For this reason, the risk/benefit calculus of adding immunotherapy for HR+/HER2-negative early breast cancer is different from metastatic triple negative breast cancer (TNBC) or even Stage II/III TNBC where the risks of morbidity and mortality from disease are higher. Here, ERBB2 is linked to triple-negative breast carcinoma.